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Abstract
Background: Mitral annular calcification (MAC) is associated with several cardiovascular disorders including coronary artery 
disease (CAD), atrial fibrillation, heart failure, ischemic stroke and increased mortality. Epicardial fat thickness (EFT) has strong 
correlation with obesity, CAD, insulin resistance, metabolic syndrome, hypertension, diabetes mellitus, and atherosclerosis. There 
are strong similarities between EFT and MAC from the aspect of  risk factors and pathogenesis. 
Objective: In this study we aimed to investigate the EFT in patients with MAC. 
Methods: The study group consisted of  78 patients with MAC. An age, gender and body mass index matched control group 
consisted of  47 subjects who admitted to echocardiography laboratory due to suspicion of  organic heart disease and eventually 
found to be free of  MAC. We measured EFT in patients with MAC and control subjects. 
Results: EFT was significantly higher in patients with MAC than in control subjects (5.7±0.9 vs. 4.4±0.6 mm respectively; P< 
0.001). Correlation analysis indicated that EFT was positively correlated with presence of  MAC (p<0.001, r=0.597). 
Conclusion: We showed that EFT was significantly elevated in patients with MAC and it was positively correlated with MAC.
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Introduction
Mitral annular calcification (MAC) is characterized by cal-
cium and lipid deposition on mitral valve ring.1  It has 
been associated with coronary artery disease (CAD), atri-
al fibrillation, heart failure, ischemic stroke and increased 
mortality.1-5 Risk factors for atherosclerotic CAD such as 
age, hypertension, diabetes mellitus and obesity are also 
risk factors for MAC.1 MAC and atherosclerosis share the 
similar clinical risk factors and the presence of  MAC may 
reflect the intensity and duration of  exposure to the risk 
factors over time.1 However exact mechanism of  associa-
tion between two entity is not purely clear.
Visceral fat tissue is an important predictor of  cardio-met-
abolic diseases. Epicardial fat is located between the myo-
cardium and visceral pericardium. Echocardiographically, 
it is identified as the relatively echo-free space between 
the outer wall of  the myocardium and the visceral layer 
of  pericardium.6 Epicardial fat is considered an important 
cardiovascular risk predictor, in view of  producing and 
releasing several adipo-cytokines.7 Epicardial fat thick-
ness (EFT) has strong correlation with obesity, impaired 
fasting glucose, insulin resistance, metabolic syndrome, 
hypertension, diabetes mellitus, and atherosclerosis.6-9
So there are similarities between EFT and MAC from 
the aspect of  risk factors and their consequences. In this 
study, we aimed to investigate the EFT in patients with 
MAC to determine any relation between EFT and MAC. 
Patient and methods
The study group consisted of  78 consecutive patients 
with MAC (41 females, 37 males, mean age 71.9±6.9 
years). The study group were prospectively selected from 
the patients who admitted to Suleyman Demirel Univer-
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sity Hospital, Cardiology out-patient clinic and echocar-
diography laboratory due to suspicion of  heart disease 
between June 2014 and May 2015. The 47 control sub-
jects (23 females, 24 males, mean age 69.7±4.7years) 
were selected from peoples who were admitted to our 
outpatient clinic and echocardiography laboratory due to 
suspicion of  heart disease at the same period and their 
echocardiographic examinations showed normal cardi-
ac findings. All patients and control subjects underwent 
medical history, physical examination, anthropometric 
measurements, electrocardiogram, and echocardiograph-
ic evaluation. Patients having coronary angiogram with 
>%50 coronary lesion, coronary bypass surgery and per-
cutaneous coronary intervention were regarded as having 
coronary artery disease. In other patients, there was no 
angina or equivalent symptoms. The study was approved 
by the institutional ethics committee and all patients gave 
their informed consent. Exclusion criteria were peri-
cardial effusion, poor echocardiographic window, heart 
failure (EF<%50), history of  chronic renal and liver dis-
ease, moderate to severe mitral and aortic regurgitation, 
moderate to severe mitral and aortic stenosis, malignancy, 
systemic or pulmonary embolism, chronic hematological 
diseases, acute or chronic inflammatory disease, autoim-
mune disease, hyperparathyroidism, hypercalcemia, hy-
perphosphatemia and a prosthetic valve. 
Echocardiography
The M-mode, two-dimensional, and Doppler echocar-
diographic examinations were obtained by using GE 
VingMed System FiVe (Norway) to asses left atrial (LA) 
diameter, interventricular septum (IVS) thickness, left 
ventricular posterior wall (LWPW) thickness, left ventric-
ular end diastolic diameter (LVEDD), left ventricular end 
systolic diameter (LVESD), left ventricular ejection frac-
tion (EF), isovolumic relaxation time (IVRT), decelera-
tion time (DT), myocardial performance index (MPI) and 
MAC. Left atrial and ventricular dimensions and left ven-
tricular EF were measured by M-mode echocardiography 
in the parasternal long axis view by using the American 
Echocardiography Society M-mode technique.10 EF was 
measured with M mode by the Teicholz method. MAC 
was defined as an intense echocardiography producing 
structure with highly reflective characteristics that was lo-
cated at the junction of  the atrioventricular groove and 
the posterior or anterior mitral leaflet on the parasternal 
long-axis, apical 4-chamber or 2-chamber, or parasternal 
short-axis view.11 The presence of  mitral and aortic insuf-
ficiency was evaluated by Doppler color flow mapping. 
EFT was identified echocardiographically as the echo-
free space between the outer wall of  the myocardium and 
the visceral layer of  pericardium. EFT was measured at 
the point on the free wall of  the right ventricle along the 
midline of  the ultrasound beam, perpendicular to the aor-
tic annulus at the end of  systole (Fig 1).8 As Iacobellis et 
al. suggested, epicardial fat is best measured at end-systo-
le, because it is compressed during diastole.8 The average 
value of  three cardiac cycles was determined as epicardial 
fat thickness.
Blood sampling
Blood samples were drawn from the antecubital vein by 
careful venipuncture in a 21 G sterile syringe without 
stasis at 08.00–10.00 AM after a fasting period of  12 h. 
Glucose, creatinine, and lipid profiles were determined 
by standard methods. Hemogram parameters were mea-
sured in a blood sample collected in dipotassium EDTA 
tubes (Vacuette). An automatic blood counter (Beck-
man-Coulter Co, Miami, FL, USA) was used for whole 
blood counts. 
Statistical analysis
Data were analyzed with the SPSS software version 
15.0 for Windows. Continuous variables from the study 
groups were reported as mean ± standard deviation, cat-
egorical variables as percentages. To compare continuous 
variables, the Student t-test was used. Categorical vari-
ables were compared with the chi-squared test. The cor-
relations between MAC, EFT and other clinical, labora-
tory and echocardiographic parameters were performed 
with Pearson and Spearman correlation analysis where 
appropriate. A p value < 0.05 was considered statistically 
significant. 
Results  
Baseline clinical features of  the study and control groups 
were summarized in Table 1. There was no statistically 
significant differences between two groups with respect 
to age, gender, body mass index and other clinical param-
eters. There was 6 (7.7%) atrial fibrillation in patients with 
MAC, and there was no patient with atrial fibrillation in 
control group. 
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Age (years) 69.7±4.7 71.9±6.9 0.06 




98.4±13.0 102.0±11.3 0.11 
BMI (kg/m2) 29.6±5.4 31.3± 7.6 0.18 
CAD n (%) 6 (12.7) 20 (25.6) 0.08 
Smoking, n (%) 5 (10.6) 5 (6.4) 0.39 
Family history, n 
(%) 2 (4.2) 5 (6.4) 0.61 
Heart rate 
(beat/min) 69.2±12.8 72.0±13.5 0.25 
SBP (mmHg) 121.2±18.6 122.8± 18.1 0.63 
DBP (mmHg) 75.1±9.3 77.5±11.1 0.20 
AF, n (%) 0 (0,0) 6 (7.7) 0.05 
ASA, n (%) 15 (31.9) 36 (46.1) 0.11 
Clopidogrel, n (%) 4 (8.5) 12 (15.3) 0.26 
OA/NOA, n(%) 0 (0.0) 4 (5.1) 0.12 
Statin, n (%) 10 (21.3) 22 (28.2) 0.39 
ACEi, n (%) 10 (21.3) 22 (28.2) 0.39 
ARB, n (%) 9 (19.1) 22 (28.2) 0.26 
CCB, n (%) 2 (4.2) 11 (14.1) 0.08 
B Blocker, n (%) 11 (23.4) 37 (47.4) 0.03* 
Diuretic, n (%) 9 (19.1) 32 (41.0) 0.01* 
          
         MAC: mitral annular calcification, M/F: male/female, BMI: body mass index, CAD:  
           coronary artery disease, SBP: systolic blood pressure, DBP: diastolic blood pressure, AF:  
           atrial fibrillation, OA: oral anticoagulan, NOA: new oral anticoagulan, ACEi:  
           angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, CCB:  
           calcium channel blocker 
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However this difference didn’t reach the statistically sig-
nificant level (p=0.05). Only B blocker and diuretic usage 
was significantly higher in the MAC group. The labora-
tory findings of  the study and control groups were sum-
marized in Table 2. There was no statistically significant 
difference between two groups. 







Glucose (mg/dl) 124.9± 67.2 128.4± 62.0 0.72 
Creatinine (mg/dl) 0.9±0.2 0.9±0.2 0.21 
Total Cholesterol (mg/dl) 180.4± 52.6 190.8± 48.1 0.26 
Triglyceride (mg/dl) 140.5± 105.8 154.8±73.9 0.37 
LDL- Cholesterol (mg/dl) 108.6± 38.0 113.6± 39.0 0.48 
HDL- Cholesterol (mg/dl) 47.7± 15.1 45.8± 11.5 0.43 
AST (mg/dl) 23.5±7.7 22.1± 8.5 0.35 
ALT (mg/dl) 20.1±14.6 18.8± 13.1 0.59 
Na (mmol/L) 138.6±2.3 136.8±14.8 0.40 
K (mmol/L) 4.3±0.4 4.4±0.4 0.22 
Ca (mg/dL) 9.1±0.5 9.2±0.6 0.54 
P  (mg/dL) 3.2±0.7 3.3±0.7 0.42 
ALP (U/L) 82.9±26.0 85.6±49.3 0,72 
Hemoglobin (g/dl) 13.4±1.9 13.1±1.6 0.37 
WBC (×109/L) 7.6±2.0 7.7±2.7 0.79 
Platelet count (×109) 248.5±90.0 243.8±65.0 0.73 
MPV (fl) 8.6±1.3 8.4±1.0 0.42 
             
            LDL-cholesterol: low density lipoprotein cholesterol, HDL-cholesterol: high density  
            lipoprotein cholesterol, AST: aspartate aminotransferase ALT: alanine aminotransferase,  
           ALP: aspartate aminotransferase, WBC: white blood cell MPV: mean platelet volume.  
           P value is for comparison between control and study population. 
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Echocardiographic findings of  the study and control 
groups were summarized in Table 3. LA diameter was 
significantly higher in patients with MAC than in con-
trol subjects (37.2± 4.4 vs. 35.5±4.0 mm respectively; 
P= 0.03). IVS thickness was significantly higher in pa-
tients with MAC than in control subjects (11.3±1.5 vs. 
10.7±1.4 mm respectively; P= 0.03). LVEDD was sig-
nificantly higher in patients with MAC than in control 
subjects (46.1±3.3 vs. 44.9±2.8 mm respectively; P= 
0.04). LVESD was significantly higher in patients with 
MAC than in control subjects (28.9±3.5 vs. 27.2±2.6 mm 
respectively; P=0.005). EFT was significantly higher in 
patients with MAC than in control subjects (5.7±0.9 vs. 
4.4±0.6 mm respectively; P< 0.001). 







Aort (mm) 25.3±2.5 25.9± 2.4           0.14 
LA (mm) 35.5±4.0 37.2± 4.4 0.03* 
IVS (mm) 10.7±1.4 11.3±1.5 0.03* 
LVPW (mm) 9.9±0.9 10.0±0.8            0.29 
LVESD (mm) 27.2±2.6 28.9±3.5 0.005* 
LVEDD (mm) 44.9±2.8 46.1±3.3 0.04* 
SPAP (mmHg) 25.5±10.8 28.7±9.6 0.08 
EF (%) 60.0±2.3 58.8±4.2 0.07 
EFT (mm) 4.4±0.6 5.7±0.9 P< 0.001 
E/A 0.7±0.1 0.8±0.4 0.13 
IVRT (ms) 82.6±19.0 84.0±13.2 0.64 
DT (ms) 192.3±40.4 190.5±34.0 0.79 
MPI 0.38±0.05 0.41±0.06 0.008* 
MAC: mitral annular calcification, LA: left atrium, IVS: Interventricular septum, LVPW: Left 
ventricular posterior wall, LVEDD: Left ventricular end diastolic diameter, LVESD: Left 
ventricular end systolic diameter, SPAP: systolic pulmonary artery pressure, EF: ejection 
fraction, EFT: epicardial fat thickness, IVRT: isovolumic relaxation time, DT: deceleration time, 
MPI: myocardial performance index, P value is for comparison between controls and overall 
study subjects *p < 0.05 (control subjects versus patients with MAC) 
Correlation analysis between EFT and other clinical 
and echocardiographic parameters were shown in Ta-
ble 4. EFT was positively correlated with presence of  
MAC (r=0.597, p<0.001). The EFT was positively cor-
related with age (r=0.390, p<0,001), alkalen phosfatase ( 
r=0.203, p=0.02), LA (r=0.193, p=0.03), IVS (r=0.260, 
p=0.003), LVESD (r=0.180, p=0.04), and waist circum-
ference (r=0.237, p=0.008). Negative correlation was 
found between EFT and alanine aminotransferase (r=-
0.183, p=0.04) and EF (r=-0.180, p=0.04).
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Table 4. The clinical and echocardiographical parameters showing the 
significant correlation with EFT. 
 
  r p  
Age 0.390 <0.001* 
ALT -0.183 0.04* 
ALP 0.203 0.02* 
LA 0.193 0.03* 
IVS 0.260 0.003* 
LVESD 0.180 0.04* 
EF -0.180 0.04* 
MPI 0.212 0.02* 
Waist circumference 0.237 0.008* 
            
           EFT: epicardial fat thickness, ALT: alanine aminotransferase, ALP: aspartate aminotransferase,  
          LA: left atrium, IVS: interventricular septum, LVESD: Left ventricular end systolic diameter,  
          EF: ejection fraction, MPI: myocardial performance index 
Discussion
In the present study, we examined EFT in patients with 
MAC. We found that EFT was significantly higher in pa-
tients with MAC than in control subjects and EFT was 
positively correlated with presence of  MAC.
MAC is associated with several cardiovascular disorders 
including CAD, atherosclerosis, heart failure, stroke and 
atrial fibrillation.1-5 Risk factors for atherosclerotic CAD 
such as age, hypertension, diabetes mellitus and obesity 
are also risk factors for MAC.12
Regional distribution of  adipose tissue, rather than gen-
eral obesity, has increasingly gained attention as a marker 
for cardiovascular disease.13 Epicardial adipose tissue is a 
true visceral fat tissue, deposited around the heart on the 
free wall of  the right ventricle, left ventricular apex and 
atrium. Previous studies showed that epicardial adipose 
tissue was associated with abdominal fat.14 Epicardial fat 
has been suggested to influence CADdevelopment due 
to its proximity to the coronary arteries and absence of  a 
physical barrier between it and the coronary artery walls 
and myocardium.
The mechanism of  the relationship between epicardial fat 
and MAC are not fully established.
Two potential mechanisms can be proposed for this as-
sociation: first, epicardial adipose tissue is a component 
of  visceral adiposity and is related to metabolic syndrome 
and cardiovascular risk factors, secondly, epicardial adi-
pose tissue acts as a paracrine and endocrine organ.6-8 It 
can secrete numerous bioactive molecules (adipokines, 
such as adiponectin, resistin) and inflammatory cyto-
kines (tumor necrosis factor–a, monocyte chemoattrac-
tant protein–1, interlukin-6, nerve growth factor, resistin, 
visfatin, omentin, leptin, plasminogen activator inhibi-
tor–1, and angiotensinogen).1-4,8,15-17 Meanwhile, Fox et al 
showed that inflammatory biomarkers (C-reactive pro-
tein, interleukin-6, monocyte chemoattractant protein-1, 
and soluble intercellular cell adhesion molecule-1) were 
increased in patients with valvular calcification.18 As a re-
sult, increased inflammatory mediators from epicardial 
adipose tissue might have an important role in pathogen-
esis of  MAC and atherosclerosis. As also mentioned be-
fore MAC is strongly associated with the pathogenesis of  
atherosclerosis due to sharing same risk factor.
On the other hand, epicardial fat also produces anti-in-
flammatory, antiatherogenic adipokines, such as adi-
ponectin and adrenomedullin.19 However, Iacebolis et al. 
showed that adiponectin expression is significantly lower 
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in epicardial fat isolated from patients with CAD.19 Nev-
ertheless, what can influence this equilibrium between 
harmful and possible protective effects is still unknown. 
Due to its anatomic proximity to the heart and the ab-
sence of  fascial bo"undaries, epicardial adipose tissue 
may interact locally and modulate the coronary arteries 
and their supplying cardiac valves through the paracrine 
or vasocrine secretion of  proinflammatory adipokines.16 
It has been shown that epicardial adipose tissue is related 
to cardiovascular risk factors and coronary artery calci-
fication.20,21 In a recent study, Parisi et al reported a sig-
nificant association between EFT measured by echocar-
diography and aortic stenosis.22  In a more recent study, 
Alnabelsi et al. showed a correlation between EFT thick-
ness measured by computerize tomography and calcium 
deposits on mitral annulus and aortic valve.23 In our study, 
we found that EFT was significantly higher in patients 
with MAC than in control subjects and EFT was positive-
ly correlated with presence of  MAC. There was no statis-
tically significant difference in CAD incidence between 
patients with MAC and controls. We think that increased 
EFT has an important role in pathogenesis of  MAC. 
EFT and MAC share the similar clinical risk factors for 
cardiovascular diseases, including age, obesity, hyperten-
sion, hyperlipidemia, diabetes mellitus and metabolic syn-
drome.1,24 In our study there was no significant difference 
between patients with MAC and controls with respect to 
cardiovascular risk factors as shown in Table 1. EFT was 
significantly higher in patients with MAC than controls 
independent of  these cardiovascular risk factors. Other 
mechanism might also play in role in this association.
There are several limitations of  the present study. First, 
the number of  patients was small. Second, our study had 
a cross-sectional design, and therefore we could not es-
tablish a cause-and-effect relationship between EFT and 
MAC. Third, echocardiographic EFT measurements 
might not exactly reflect the amount of  total EFT. How-
ever, previous studies reported that echocardiograph-
ic EFT measurements are well correlated with the total 
volume of  epicardial adipose tissue detected with other 
radiologic methods.25,26 Moreover, echocardiographic as-
sessment of  epicardial fat tissue would certainly be less 
expensive  than computerized tomography and echocar-
diography is routinely performed in high-risk cardiac pa-
tients. Because of  that, this objective non-invasive mea-
sure may be readily available with no extra cost.
Conclusion
Our findings suggest that echocardiographic EFT mea-
surement could provide additional information on assess-
ing cardiovascular risk. Individuals with increased EFT 
should receive more attention to reduce unfavorable car-
diovascular risk factors and the development of  future 
cardiovascular events.
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